PT  - JOURNAL ARTICLE
AU  - González-Álvarez, Julio
TI  - World Science against COVID-19: Gender and Geographical Distribution of Research
AID  - 10.1101/2021.09.29.21264261
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.29.21264261
4099  - http://medrxiv.org/content/early/2021/09/29/2021.09.29.21264261.short
4100  - http://medrxiv.org/content/early/2021/09/29/2021.09.29.21264261.full
AB  - In just a year and a half, an enormous volume of scientific research has been generated throughout the world to study a virus/disease that turned into a pandemic. All the articles on COVID-19 or SARS-CoV-2 included in the SCI-EXPANDED database (Web of Science), signed by more than a third of a million of authorships, were analyzed. Gender could be identified in 92% of the authorships. Women represent 40% of all authors, a similar proportion as first authors, but just 30% as last/senior authors. The pattern of collaboration shows an interesting finding: when a woman signs as a first or last/senior author, the article byline approximates gender parityAccording to the corresponding address, the USA shares 22.8% of all world articles, followed by China (14.4%), Italy (7.8%), the UK (5.8%), India (4.2%), Spain (3.8%), Germany (3.6%), France (2.9%), Turkey (2.5%), and Canada (2.4%).Despite their short lives, the papers received an average of 11 citations. The high impact of papers from China is striking (25.1 citations; the UK, 12.4 citations; the USA, 11.3 citations), presumably because the disease emerged in China, and the first publications (very cited) came from there.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThis work was completed with resources provided by the University Jaume I of Castellon (Spain).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work did not require ethical approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary Information and Data available at the following link: http://www.langproc.uji.es/COVID/World_Science_against_COVID.htm